Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_assertion type Assertion NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_head.
- NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_assertion description "[We also show that VAAST 2.0 outperforms KBAC, WSS, SKAT, and variable threshold (VT) using published case-control datasets for Crohn disease (NOD2), hypertriglyceridemia (LPL), and breast cancer (CHEK2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_provenance.
- NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_assertion evidence source_evidence_literature NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_provenance.
- NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_assertion SIO_000772 23836555 NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_provenance.
- NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_assertion wasDerivedFrom befree-2016 NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_provenance.
- NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_assertion wasGeneratedBy ECO_0000203 NP1092322.RAFD8Mjd5z9xGYx1bxur6jZsYpBn2rHG2IXTm6AzzDYX4130_provenance.